L4545
L-798106
≥98% (HPLC)
别名:
(2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C27H22BrNO4S
化学文摘社编号:
分子量:
536.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
solubility
DMSO: >20 mg/mL
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
storage temp.
2-8°C
SMILES string
COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c2ccccc2Cc3ccc4ccccc4c3
InChI
1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+
InChI key
ODTKFNUPVBULRJ-NTCAYCPXSA-N
Application
Biochem/physiol Actions
L-798106 is a potent, selective prostanoid receptor EP3-selective antagonists.
L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity.
Features and Benefits
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable